Octreotide Injection

Introduction Overview

Generic Name

octreotide injection

Brand Name

Sandostatin

Dosage Form

Injection (subcutaneous, intravenous, intramuscular), Long-acting depot intramuscular injection

Drug Class

Somatostatin and somatostatin analogs

Pharmacokinetics

Absorption:
Octreotide is administered parenterally via subcutaneous, intravenous, or intramuscular routes. After subcutaneous injection, octreotide is rapidly absorbed, with peak plasma concentrations achieved within 30 minutes. The absolute bioavailability via subcutaneous administration is approximately 80-100%. Intravenous administration leads to immediate systemic availability. The long-acting depot formulation (Sandostatin LAR Depot) achieves a slow and sustained release when given intramuscularly, maintaining therapeutic plasma levels over a 4-week period, thereby improving compliance.

Distribution:
Octreotide distributes extensively throughout the body, with an apparent volume of distribution ranging from approximately 0.27 to 0.38 L/kg, indicating distribution beyond the plasma compartment into extracellular fluids. It binds moderately to plasma proteins (approximately 65%), which influences its pharmacokinetic profile. Tissue penetration includes the pituitary gland and gastrointestinal tract, where receptor-mediated action occurs. The distribution phase is rapid after intravenous administration.

Metabolism:
Octreotide undergoes minimal hepatic metabolism; the parent compound is the primary active entity in circulation. Its enzymatic degradation primarily occurs by peptidase enzymes in tissues and plasma. The metabolic pathways are not fully oxidative or conjugative as in many small molecules but proceed via peptide bond cleavage. The metabolism is relatively stable regardless of liver impairment, although severe hepatic dysfunction can slow clearance.

Elimination:
The plasma elimination half-life of octreotide varies depending on the route: approximately 90 to 120 minutes after subcutaneous or intravenous administration. The drug is predominantly eliminated via renal excretion, with about 40-60% of unchanged drug excreted in urine. Impaired renal function leads to decreased clearance and prolonged half-life, necessitating cautious dosing and monitoring in patients with renal insufficiency. The long-acting depot formulation provides a sustained plasma concentration due to slow release from the injection site, with elimination half-life extended over several days to weeks.

Dosage Forms

Available Dosage Forms:
- Sandostatin Injection: immediate-release solution for injection administered via subcutaneous (SC), intravenous (IV), or intramuscular (IM) routes.
- Sandostatin LAR Depot: long-acting intramuscular (intragluteal) suspension for depot injection given every 4 weeks.

Dosages for Adults and Adolescents:
- Carcinoid Tumor:
* Initial dose: 100 to 600 mcg per day, administered IV or SC in 2 to 4 divided doses.
* Median daily dose reported as 450 mcg; doses between 50 to 1500 mcg per day have shown benefit.
* Sandostatin LAR Depot: initial dose 20 mg IM every 4 weeks for 2 months, followed by dose adjustment (10-30 mg every 4 weeks).
- Vasoactive Intestinal Peptide Tumor (VIPoma):
* Initial dose: 200 to 300 mcg per day IV or SC in divided doses.
* Maintenance dose: 150 to 750 mcg per day; doses above 450 mcg/day typically unnecessary.
* Long-acting depot dosing similar to carcinoid tumor regimen.
- Acromegaly:
* Initial dose: 50 mcg IV or SC three times daily.
* Maintenance dose: usually 100 mcg three times daily; maximum 500 mcg three times daily.
* Long-acting depot formulation initial dose: 20 mg IM every 4 weeks for 3 months, then titrated to 10–40 mg every 4 weeks based on response.

Specific Patient Populations:
- Pediatric use: Not approved for use in patients younger than 18 years.
- Renal impairment: Dose adjustments may be necessary due to decreased clearance.
- Hepatic impairment: Monitor as clearance may be altered.
- Switching to Long-Acting Formulation: Tolerability with short-acting product should be established for at least 2 weeks prior to initiating LAR Depot therapy to minimize symptom exacerbation.
- Injection Technique: Rotate injection sites with SC injections to prevent local tissue irritation; LAR Depot requires IM injection by healthcare professional.

Clinical Guidelines:
- Dose titration guided by biochemical markers such as insulin-like growth factor-1 (IGF-1) and growth hormone levels for acromegaly.
- In carcinoid and VIPoma syndromes, dosing is adjusted based on symptomatic control of diarrhea and flushing episodes.
- Frequent monitoring and follow-up labs recommended during therapy to assess efficacy and adverse effects.

Mechanism Of Action

Sandostatin (octreotide) is a synthetic octapeptide analog of natural somatostatin, a regulatory hormone widely expressed in the hypothalamus, pancreas, and gastrointestinal tract. The primary molecular mechanism involves binding to somatostatin receptors (SSTR), predominantly the subtype 2 (SSTR2) and subtype 5 (SSTR5) receptor subtypes present on target cells. Upon receptor binding, Sandostatin mimics somatostatin activity by inhibiting secretion of various hormones and peptides.

At the cellular level, Sandostatin activates G-protein coupled receptor signaling pathways, leading to decreased cyclic AMP production and calcium influx in secretory cells. This results in suppressed exocytosis of secretory granules, thereby reducing release of hormones such as growth hormone (GH) from the anterior pituitary, insulin and glucagon from pancreatic islets, and vasoactive intestinal peptides from neuroendocrine tumors. The drug also inhibits secretion of gastrointestinal hormones including gastrin, cholecystokinin, and serotonin.

Biochemically, this inhibition of hormone release translates into clinical effects: in acromegaly, reduced GH and IGF-1 levels lead to decreased pathological growth and symptom alleviation. In carcinoid syndrome and VIPomas, reduced secretion of serotonin, vasoactive intestinal peptide, and other tumor-derived peptides lessen severe diarrhea and flushing episodes. Additionally, Sandostatin reduces splanchnic blood flow and gastric emptying, contributing to its symptomatic relief effects.

Comparatively, Sandostatin shows higher receptor affinity and longer duration of action than native somatostatin, which has a very short half-life. Unlike some newer analogs targeting broader receptor subtypes, octreotide's preferential binding to SSTR2 renders it effective in tumors expressing this receptor profile. Clinical studies have demonstrated that its somatostatin receptor-mediated modulation improves symptom control and biochemical parameters in neuroendocrine tumors and acromegaly, with a tolerable safety profile documented in multiple trials and real-world use.

Pharmacological Actions

Inhibits secretion of growth hormone by binding to somatostatin receptors on anterior pituitary cells.
Suppresses release of insulin and glucagon from pancreatic islet cells, modulating blood glucose levels.
Reduces secretion of gastrointestinal hormones such as gastrin, cholecystokinin, and vasoactive intestinal peptide (VIP).
Decreases splanchnic blood flow and gastric motility, aiding in symptom control of diarrhea and flushing.
Inhibits secretion of serotonin and other vasoactive substances from neuroendocrine tumors (carcinoid syndrome).
Reduces pancreatic exocrine secretions, contributing to reduced gastric acid output.
Exerts anti-proliferative effects on certain neuroendocrine tumor cells via receptor-mediated pathways.
Modulates various intracellular signaling cascades, including inhibition of adenylate cyclase and reduction of intracellular calcium.
Prolongs inhibitory effects compared to natural somatostatin due to enhanced receptor affinity and longer half-life.
Reduces hormone-mediated symptoms such as acromegaly manifestations, carcinoid flushing, and VIPoma-induced watery diarrhea.

Therapeutic Or Clinical Uses

Treatment of acromegaly to reduce elevated growth hormone and insulin-like growth factor-1 (IGF-1) levels in patients inadequately controlled by surgery or radiotherapy.
Symptomatic management of carcinoid syndrome including severe diarrhea and flushing caused by metastatic carcinoid tumors.
Treatment of vasoactive intestinal peptide-secreting tumors (VIPomas) to reduce profuse watery diarrhea.
Control of symptoms in certain neuroendocrine tumors by inhibiting secretion of serotonin and other vasoactive substances.
Adjunctive therapy for gastrointestinal bleeding due to varices by reducing splanchnic blood flow (off-label use).
Reduction of hormone hypersecretion in patients with certain pancreatic endocrine tumors.
Used in diagnostic procedures for localization of somatostatin receptor-positive tumors via receptor scintigraphy.
Palliative management in malignant bowel obstruction caused by neuroendocrine tumors.
Treatment of certain secretory diarrhea and dumping syndrome associated with surgery or endocrine disorders (off-label uses).
Management of acromegaly-related symptoms such as headache, sweating, and soft tissue swelling.

Side Or Adverse Effects

Gallstone formation and cholelithiasis due to decreased gallbladder motility and bile stasis.
Gastrointestinal disturbances including nausea, vomiting, abdominal pain, diarrhea, and flatulence.
Injection site reactions such as pain, redness, or swelling after subcutaneous or intramuscular administration.
Headache and dizziness commonly reported, possibly related to systemic effects.
Bradycardia, irregular heartbeats, and other cardiac conduction abnormalities in some patients.
Hyperglycemia caused by insulin secretion inhibition, leading to increased blood glucose levels.
Hypoglycemia resulting from reduced glucagon secretion or insulin fluctuations, particularly in diabetic patients.
Hypothyroidism symptoms including fatigue, dry skin, joint pain, muscle weakness, and cold intolerance.
Fatigue and asthenia possibly due to hormonal modulation and systemic effects.
Rare allergic reactions including urticaria, angioedema, and anaphylaxis.
Elevations in liver enzymes reflecting hepatic stress or injury.
Weight loss in some patients due to gastrointestinal side effects.
Pancreatitis reported infrequently but requires monitoring.
Constipation or severe gastrointestinal motility disturbances needing medical attention.
Rare neurological symptoms such as muscle pain and weakness.

Precautions

Use with caution in patients with diabetes mellitus due to potential effects on glucose metabolism and risk of hypoglycemia or hyperglycemia.
Monitor patients with gallbladder disease closely, as octreotide may precipitate gallstone formation.
Caution advised in patients with cardiac disease, heart rhythm disorders, or hypertension due to potential for arrhythmias and bradycardia.
Regular monitoring of thyroid function is recommended owing to risk of hypothyroidism.
Close observation and dose adjustment may be necessary in patients with renal or hepatic impairment.
Patients receiving Sandostatin should be monitored for signs of pancreatitis.
Avoid abrupt discontinuation in patients with neuroendocrine tumors as rebound symptoms may occur.
Proper training on injection technique and safe handling of sharps is essential to prevent infection and injury.
Pregnant or breastfeeding women should only use Sandostatin if clearly needed and after consulting their healthcare provider.
Adjust doses cautiously in elderly patients due to altered pharmacokinetics and comorbidities.
Frequent lab monitoring including blood counts, liver and kidney function tests, and glucose levels is recommended during therapy.
Patients should inform healthcare providers of all existing medical conditions prior to initiation.
Potential interference with diagnostic tests involving hormone levels or imaging due to biochemical effects of the drug.
Use birth control during treatment as octreotide may alter hormone balance affecting fertility.
Patients with history of pancreatitis require close monitoring during therapy.

Warnings

Not for use in patients with known hypersensitivity to octreotide or any component of the formulation.
Risk of serious cardiac adverse effects including bradycardia, arrhythmias, and conduction abnormalities.
Possibility of gallbladder abnormalities including cholelithiasis occurring during therapy.
Potential for severe hypoglycemia or hyperglycemia requiring monitoring and dose adjustments.
Use caution in patients with severe renal or hepatic dysfunction as clearance may be decreased.
Monitor thyroid function due to risk of hypothyroidism with long-term use.
Injection technique errors can lead to local site infections or injury; proper education is mandatory.
Discontinue or adjust dosing with any signs of pancreatitis or severe gastrointestinal symptoms.
Potential for masking symptoms of hypoglycemia in diabetic patients; patients should be counseled accordingly.
Patients should not miss follow-up appointments for laboratory testing to evaluate therapy effectiveness and adverse effects.
Use during pregnancy or breastfeeding only if benefits outweigh risks; fetal effects are not well studied.
Not approved for pediatric use in persons under 18 years of age.
Abrupt withdrawal can worsen symptoms in some patients; dose tapering is advisable under physician guidance.
Some patients may require adjunctive medications during dose transitions, especially when switching to long-acting formulations.
Patients should be advised to seek immediate medical attention for signs of allergic reactions or severe side effects.

Contraindication

Known allergy or hypersensitivity to octreotide or any ingredient in Sandostatin formulations.
Use is contraindicated in patients with hypersensitivity reactions including anaphylaxis to this class of drugs.
Patients with untreated gallbladder disease should be evaluated carefully before initiating treatment.
Contraindicated in pediatric patients under 18 years due to lack of established safety and efficacy.
Avoid use in patients with severe cardiac conduction disturbances unless benefit outweighs risk and under strict monitoring.
Patients with severe renal failure requiring dialysis may require careful consideration and dose adjustment; not absolutely contraindicated but used with caution.
Concurrent use with other drugs causing similar adverse effects, such as severe bradycardia, should be avoided.
Contraindicated in patients with known hypersensitivity to preservatives or excipients in specific formulations.
Use in pregnancy contraindicated unless no safer alternative exists due to insufficient safety data.
Avoid in patients with acute pancreatitis until clinical resolution.
May be contraindicated in cases of hypersensitivity to somatostatin analogs such as lanreotide.
Severe hepatic impairment requires careful assessment prior to use to avoid toxicity.

Drug Interactions

May enhance the hypoglycemic effects of insulin and oral antidiabetic drugs, increasing risk of hypoglycemia.
Can reduce absorption and effectiveness of cyclosporine by decreasing gastrointestinal motility and blood flow.
Concomitant use with bromocriptine may potentiate inhibitory effects on hormone secretion.
Potential interaction with heart and blood pressure medications, necessitating close cardiac monitoring.
May alter metabolism of certain drugs through effects on hepatic enzyme activity, although data is limited.
Octreotide's inhibition of gastrointestinal hormones may affect absorption of oral medications.
Use caution when given with other agents that affect heart rate or conduction, such as beta-blockers or calcium channel blockers.
Concurrent use with insulin or glucose-lowering agents requires careful blood glucose monitoring and dose adjustment.
May interfere with absorption of fat-soluble vitamins due to reduced pancreatic secretions.
Additive effects on gastrointestinal motility when combined with other GI-active drugs.
Potential interaction with antineoplastic agents, although limited clinical data is available.
Concomitant use with drugs affecting thyroid function should be monitored closely due to octreotide’s effect on thyroid hormone levels.
Interaction with warfarin and other anticoagulants is not well established but monitoring is advisable.
Herbal supplements and vitamins that alter hormone metabolism may have additive or opposing effects.
Monitor for adverse effects when combined with other peptide hormones or somatostatin analogs.

Preparations Of The Drug

Sandostatin immediate-release injection: octreotide acetate solution available for subcutaneous or intravenous injection.
Sandostatin LAR Depot: microsphere-based long-acting intramuscular suspension for sustained release every 4 weeks.
Preservative-free ampules for single use requiring proper storage and handling.
Self-administered subcutaneous injection kits with sterile needles and syringes, requiring patient education.
Pre-filled syringes or vials for injection prepared in hospital settings or specialized pharmacies.
Refrigerated storage recommended for unopened ampules; unopened vials may be kept at room temperature up to 14 days before use.
Instructional materials accompanying each preparation including dosage, injection technique, and disposal guidelines.
No oral formulations currently approved; research ongoing into alternative delivery routes.
Preparations available with varying concentrations suited for titration and maintenance therapy.
Multi-dose vials are not standard; single-use ampules reduce risk of contamination.
Combination with diluents provided by manufacturer to ensure solution stability prior to injection.
LAR Depot powders require reconstitution before intramuscular administration by a healthcare professional.
Limited generic formulations; Sandostatin remains a branded medication with established formulations.
Packaging designed to protect from light and maintain peptide stability.
Disposal of needles and injection equipment to follow local regulations to minimize risk of injury or infection.